

**OCREVUS ZUNOVO Vials 920 mg/23 ml**
Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**SECTION 1. IDENTIFICATION**

Product name : OCREVUS ZUNOVO Vials 920 mg/23 ml

Product code : RO496-4913/F09-02

Common name(s),  
synonym(s) of the substance : Ocrevus SC 40 mg/ml**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Not a hazardous substance or mixture.

**GHS label elements**

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Ocrelizumab	637334-45-3	4
Trehalose (D+)-, 2H <sub>2</sub> O	6138-23-4	9.1
Sodium acetate trihydrate	6131-90-4	0.22
L-Methionine	63-68-3	0.15
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.06
Acetic acid	64-19-7	0.02
Hyaluronidase	757971-58-7	0.0017

**OCREVUS ZUNOVO Vials 920 mg/23 ml**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

Water

7732-18-5

86

**SECTION 4. FIRST AID MEASURES**

General advice : Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.

In case of skin contact : Wash off with soap and water.

In case of eye contact : Remove contact lenses.  
Protect unharmed eye.  
If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : Carbon oxides  
Carbon monoxide  
Nitrogen oxides (NOx)  
Sulfur oxides

Further information : Standard procedure for chemical fires.  
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**OCREVUS ZUNOVO Vials 920 mg/23 ml**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.

Environmental precautions : If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).  
Keep in suitable, closed containers for disposal.

---

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protect from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass, Vials

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ocrelizumab	637334-45-3	IOEL	0.02 mg/m3	Roche Industrial Hygiene Committee (RIHC)
Hyaluronidase	757971-58-7	IOEL	0.00006 mg/m3	Roche

**OCREVUS ZUNOVO Vials 920 mg/23 ml**
Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

				Industrial Hygiene Committee (RIHC)
--	--	--	--	--

**Personal protective equipment**

Respiratory protection	: General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
Hand protection	
Material	In case of contact through splashing:
Break through time	: Nitrile rubber
Glove thickness	: > 30 min
	: > 0.11 mm
Material	In case of full contact:
Break through time	: butyl-rubber
Glove thickness	: > 480 min
	: > 0.4 mm
Remarks	: Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.
Eye protection	: Safety glasses
Skin and body protection	: Protective suit
Hygiene measures	: General industrial hygiene practice.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	: Aqueous solution, Clear liquid, sterile
Color	: colorless
Odor	: No data available
Odor Threshold	: No data available
pH	: 5.3
Melting point/ range	: No data available

# SAFETY DATA SHEET

**Genentech**  
A Member of the Roche Group

## OCREVUS ZUNOVO Vials 920 mg/23 ml

Version 1.0 Revision Date: 06/15/2025 Date of last issue: - Date of first issue: 06/15/2025

Boiling point/boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Self-ignition : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : completely miscible

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : No data available

Oxidizing properties : No data available

Particle characteristics

Particle Size Distribution : Not applicable

---

## SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Proteins are temperature-sensitive; the thermal denaturation

**OCREVUS ZUNOVO Vials 920 mg/23 ml**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created

Stable under normal conditions.

Possibility of hazardous reactions : Stable under recommended storage conditions.  
No hazards to be specially mentioned.

Conditions to avoid : No data available

No data available

Incompatible materials : No data available  
Not applicable

Hazardous decomposition products : No data available  
No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified due to lack of data.

**Components:****Trehalose (D+)-, 2H<sub>2</sub>O:**

Acute oral toxicity : LD50 (Rat): 16,000 mg/kg

**Ocrelizumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : LD0 (cynomolgus monkey): 100 mg/kg  
Application Route: i.v.  
GLP: yes

**Hyaluronidase:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

**Skin corrosion/irritation**

Not classified due to lack of data.

**OCREVUS ZUNOVO Vials 920 mg/23 ml**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Components:****Hyaluronidase:**

Remarks : This information is not available.

**Serious eye damage/eye irritation**

Not classified due to lack of data.

**Components:****Hyaluronidase:**

Remarks : This information is not available.

**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**Components:****Hyaluronidase:**

Remarks : May cause sensitization of susceptible persons by skin contact or by inhalation of dust.

**Germ cell mutagenicity**

Not classified due to lack of data.

**Carcinogenicity**

Not classified due to lack of data.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified due to lack of data.

**Components:****Ocrelizumab:**Effects on fetal development : Species: cynomolgus monkey  
Application Route: i.v.  
Dose: 100 milligram per kilogram  
Result: No teratogenic effects., No embryotoxic effects.**STOT-single exposure**

Not classified due to lack of data.

## OCREVUS ZUNOVO Vials 920 mg/23 ml

Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Components:****Hyaluronidase:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**STOT-repeated exposure**

Not classified due to lack of data.

**Components:****Hyaluronidase:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Repeated dose toxicity****Components:****Hyaluronidase:**

Species : cynomolgus monkey  
NOAEL : 2 mg/kg/w  
Application Route : s.c.  
Exposure time : 39 weeks

**Aspiration toxicity**

Not classified due to lack of data.

**Components:****Hyaluronidase:**

No data available

**Further information****Product:**

Remarks : No data available

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Trehalose (D+)-, 2H2O:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l  
Exposure time: 96 h  
Test Type: static test

Toxicity to fish (Chronic toxicity) : NOEC (Danio rerio (zebra fish)): 100 mg/l  
Exposure time: 96 d

**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

## OCREVUS ZUNOVO Vials 920 mg/23 ml

Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Ocrelizumab:**

Toxicity to fish : LC50 (Poecilia reticulata (guppy)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
GLP: yes  
Remarks: nominal concentration

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Test Type: Immobilization  
Method: OECD Test Guideline 202  
GLP: yes  
Remarks: nominal concentration

NOEC (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Test Type: Immobilization  
Method: OECD Test Guideline 202  
GLP: yes  
Remarks: nominal concentration

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l  
Exposure time: 72 h  
Test Type: Growth inhibition  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: nominal concentration

EyC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l  
Exposure time: 72 h  
Test Type: Growth inhibition  
Method: OECD Test Guideline 201  
GLP: yes  
Remarks: nominal concentration

**Hyaluronidase:****Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**OCREVUS ZUNOVO Vials 920 mg/23 ml**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Persistence and degradability****Components:****Trehalose (D+)-, 2H2O:**

Biodegradability : aerobic  
Inoculum: activated sludge, non-adapted  
Biochemical oxygen demand  
Result: Readily biodegradable.  
Biodegradation: 73 %  
Method: OECD Test Guideline 301A  
Remarks: The 10 day time window criterion is not fulfilled.

aerobic  
Inoculum: activated sludge, non-adapted  
Dissolved organic carbon (DOC)  
Result: Readily biodegradable.  
Biodegradation: 98 %  
Method: OECD Test Guideline 301A

**Ocrelizumab:**

Biodegradability : aerobic  
Theoretical oxygen demand  
Result: Readily biodegradable.  
Biodegradation: 93 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F  
GLP: yes

**Hyaluronidase:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Bioaccumulative potential****Components:****Trehalose (D+)-, 2H2O:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Ocrelizumab:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Hyaluronidase:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Mobility in soil**

No data available

**OCREVUS ZUNOVO Vials 920 mg/23 ml**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025**Other adverse effects****Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : No data available

**Components:****Hyaluronidase:**

Additional ecological information : No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

**Special precautions for user**

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

**OCREVUS ZUNOVO Vials 920 mg/23 ml**
Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

---

**SECTION 15. REGULATORY INFORMATION**
**CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

Components	CAS-No.	Component TPQ (lbs)
<b>SARA 311/312 Hazards</b>	:	No SARA Hazards

**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Acetic acid	64-19-7	>= 0 - < 0.1 %
-------------	---------	----------------

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Acetic acid	64-19-7	>= 0 - < 0.1 %
-------------	---------	----------------

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations**
**Massachusetts Right To Know**
**Pennsylvania Right To Know**

Water	7732-18-5
Trehalose (D+)-, 2H2O	6138-23-4
Ocrelizumab	637334-45-3
Acetic acid	64-19-7

**Maine Chemicals of High Concern**
**Vermont Chemicals of High Concern**
**Washington Chemicals of High Concern**
**The ingredients of this product are reported in the following inventories:**

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Ocrelizumab

**OCREVUS ZUNOVO Vials 920 mg/23 ml**
Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025


## Hyaluronidase

NZIoC	:	On the inventory, or in compliance with the inventory
ENCS	:	Not in compliance with the inventory
ISHL	:	Not in compliance with the inventory
KECI	:	Not in compliance with the inventory
PICCS	:	Not in compliance with the inventory
IECSC	:	Not in compliance with the inventory
TCSI	:	Not in compliance with the inventory
TSCA	:	Product contains substance(s) not listed on TSCA inventory.
TECI	:	Not in compliance with the inventory

**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

**SECTION 16. OTHER INFORMATION****Further information****NFPA 704:****HMIS® IV:**

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "/" represents a chronic hazard, while the "0" represents the absence of a chronic hazard.

**Full text of other abbreviations**

**OCREVUS ZUNOVO Vials 920 mg/23 ml**Version  
1.0Revision Date:  
06/15/2025Date of last issue: -  
Date of first issue: 06/15/2025

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/15/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404